.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,999,999

« Back to Dashboard

Claims for Patent: 8,999,999

Title:Use of inhibitors of Bruton's tyrosine kinase (Btk)
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Inventor(s): Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA), Fyfe; Gwen (San Francisco, CA), Hedrick; Eric (Summit, NJ), Loury; David J. (San Jose, CA), Mody; Tarak D. (Sunnyvale, CA)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:13/747,322
Patent Claims: 1. A method for treating relapsed or refractory chronic lymphocytic leukemia or relapsed or refractory small lymphocytic leukemia in an individual comprising administering to the individual in need thereof once per day between about 280 mg to about 840 mg of an oral dose of an irreversible inhibitor of Bruton's tyrosine kinase (Btk), having the structure: ##STR00047##

2. The method of claim 1, wherein the subject has high risk relapsed or refractory chronic lymphocytic leukemia.

3. The method of claim 1, wherein the subject has nucleic acid deletion in chromosome 17.

4. The method of claim 3, wherein the deletion is in 17p.

5. The method of claim 4, wherein the deletion is in 17p13.

6. The method of claim 1, wherein the subject has nucleic acid deletion in chromosome 11.

7. The method of claim 6, wherein the deletion is in 11q.

8. The method of claim 7, wherein the deletion is in 11q22.

9. The method of claim 1, further comprising administering to the individual an additional cancer treatment regimen.

10. The method of claim 9, wherein the additional cancer treatment regimen comprises bendamustine, bortezomib, CAL-101, chlorambucil, cyclophosphamide, dexamethasone, docetaxel, doxorubicin, endostatineverolimus, etoposide, fludarabine, fostamatinib, hydroxydaunorubicin, ibritumomab, ifosphamide, lenalidomide, mesalazine, ofatumumab, paclitaxel, pentostatin, prednisone, rituximab, temsirolimus, thalidomide, tositumomab, vincristine, or a combination thereof.

11. The method of claim 1, further comprising administering to the individual rituximab.

12. The method of claim 1, further comprising administering to the individual bendamustine.

13. The method of claim 1, further comprising administering to the individual rituximab and bendamustine.

14. The method of claim 1, further comprising administering to the individual rituximab, fludarabine and cyclophosphamide.

15. The method of claim 1, further comprising administering to the individual rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.

16. The method of claim 1, wherein the Btk inhibitor is administered orally.

17. The method of claim 1, wherein the Btk inhibitor is in the form of a solid oral dosage form.

18. The method of claim 1, wherein the once per day oral dose of the Btk inhibitor administered is about 280 mg/day, about 420 mg/day, about 560 mg/day, or about 840 mg/day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc